BlackRock Advisors’s Theriva Biologics TOVX Stock Holding History

BlackRock Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$33K	Hold	5	–	–	﹤0.01%	3351
2016 Q3	$74K	Buy	5 +1	+25%	+$15K	﹤0.01%	3139
2016 Q2	$65K	Buy	4 +2	+100%	+$37.6K	﹤0.01%	3152
2016 Q1	$32K	Hold	2	–	–	﹤0.01%	3305
2015 Q4	$31K	Hold	2	–	–	﹤0.01%	3359
2015 Q3	$31K	Hold	2	–	–	﹤0.01%	3414
2015 Q2	$38K	Buy	2 +1	+100%	+$20.1K	﹤0.01%	3368
2015 Q1	$24K	Hold	1	–	–	﹤0.01%	3416
2014 Q4	$16K	Buy	+1	New	+$13.4K	﹤0.01%	3552

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BlackRock Advisors's TOVX Position: Q4 2016 in Review

BlackRock Advisors held its Theriva Biologics (TOVX) position steady in Q4 2016 at 5 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #3351.

BlackRock Advisors first reported a position in TOVX in Q4 2014 and has held it in 9 quarters since. The position peaked at $74K in Q3 2016. 70 funds tracked by Wall St. Rank hold TOVX as of Q4 2016.

BlackRock Advisors held 5 shares of Theriva Biologics worth $33K as of Q4 2016.
BlackRock Advisors left its Theriva Biologics share count unchanged in Q4 2016.
Theriva Biologics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3351 holding.
BlackRock Advisors first reported a position in Theriva Biologics in Q4 2014 and has held it in 9 quarters since.
BlackRock Advisors's Theriva Biologics position peaked at $74K in Q3 2016.
70 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.